Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards

CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
September 25, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationIntermediate-dose study arm: enrollment complete Initial immunologic data from low...
September 16, 2018 01:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Responds to Unfounded Allegations in Globes Article

CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12,...
September 16, 2018 01:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Responds to Unfounded Allegations in Globes Article

CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12,...
August 28, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
August 15, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development

CAMBRIDGE, Mass., Aug. 15, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as...
August 06, 2018 16:15 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth Conference

CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
July 26, 2018 07:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate Update

-- Pivotal Phase 3 program for Sci-B-Vac® Hepatitis B vaccine continues to advance towards topline data expected mid-year 2019 -- -- Positive safety and immunogenicity data from Phase 1 study of...
July 09, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit

CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
June 19, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right